Jiang Sitong, Guo Fengzhu, Li Lin
Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
Department of Medical Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China.
Biochim Biophys Acta Rev Cancer. 2025 Jul;1880(3):189320. doi: 10.1016/j.bbcan.2025.189320. Epub 2025 Apr 11.
Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality worldwide, with Brain Metastases serving as a significant adverse prognostic factor. The blood-brain barrier poses a substantial challenge in the treatment of brain metastases, as it restricts the penetration of many anticancer agents. Novel immunotherapy, such as immune checkpoint inhibitors (ICIs) have emerged as promising treatment for NSCLC and its associated brain metastases. This review summarizes the biological mechanism underlying NSCLC brain metastases and provides an overview of the current landscape of immunotherapy, exploring the mechanism of action and clinical applications of these advanced treatments.
非小细胞肺癌(NSCLC)是全球癌症相关死亡的主要原因,脑转移是一个重要的不良预后因素。血脑屏障在脑转移瘤的治疗中构成了重大挑战,因为它限制了许多抗癌药物的渗透。新型免疫疗法,如免疫检查点抑制剂(ICIs)已成为NSCLC及其相关脑转移瘤的有前景的治疗方法。本综述总结了NSCLC脑转移的生物学机制,并概述了当前免疫疗法的概况,探讨了这些先进治疗方法的作用机制和临床应用。